Cancer vaccine

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights podcast: 2 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights vodcast: 2 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the launch of an… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

This week in drug discovery (26-30 August) 

News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for… Read More

#News

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

Vaccine production
#Cancer vaccine #mRNA #mRNA-based vaccines #Oncology #Personalised medicine #University of Queensland

Personalised cancer vaccines to be produced at Queensland lab

A new facility at The University of Queensland, Australia, will provide researchers with cancer vaccines tailored to individual patients. The lab at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will bring together the equipment and expertise to enable the design, manufacture and delivery of new… Read More

#News

Cancer cells
#ASCO #Cancer therapeutics #Cancer treatment #Cancer vaccine #Oncology

Five 2024 breakthroughs in cancer drug research

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More

#Cancer Research #News #Trending News

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

GBP pound sterling funding
#Biotech #Cancer Research Horizons #Cancer vaccine #Oncology #Start-ups #University of Oxford

Cancer vaccine developer secures £12.8m

Oxford University spin-out Infinitopes Precision Immunomics has completed a £12.8 ($16) million seed funding round led by Octopus Ventures. The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital,… Read More

#Business & Investment #News #Start-up Zone

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

New DDW Highlights podcast: 29 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The leading news story this week has been the launch of a new clinical… Read More

#News

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

This week in drug discovery (22-26 April) 

News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer. The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in… Read More

#News

Doctor prepares vaccine
#Cancer vaccine #Genetic diseases #ImmunityBio #Immunology / Virology & Vaccines #Oncology #Phase II trial

Combination cancer vaccine to be assessed in Phase II trial

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More

#Cancer Research #News

Vaccine vial and syringe
#Cancer vaccine #Imperial College London #Moderna #mRNA-based vaccines #Oncology #Phase I trial

First UK patients receive experimental mRNA therapy for cancer

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More

#Cancer Research #News #Trending News